Antibody Drug Conjugate News and Research

RSS

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

Collaboration classification useful for Japanese lung cancer patients

Epidermal growth factor receptor status and prognosis in Japanese patients can be predicted by a recently developed lung adenocarcinoma classification system, say researchers.

23 Jul 2014

Apparent diffusion coefficient does not reflect cytotoxicedema on uninjured side after TBI

It is currently difficult to treat traumatic brain injury (TBI) in the clinic. There are abundant neural network connections and humoral regulation mechanisms between the cerebral hemispheres.

15 Jul 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

PolyTherics Limited, a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge antibody drug conjugate ("ADC") collaboration with MacroGenics Inc, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.

11 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

Omnicell’s Pandora business analytics solutions now available in the Middle East markets

Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.

From Omnicell, Inc. 27 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

ADC values and diffusion weighted imaging can be used to detect early cerebral infarction

Supratentorial cerebral infarction can cause functional inhibition of remote regions such as the cerebellum, which may be relevant to diaschisis. This phenomenon is often analyzed using positron emission tomography and single photon emission CT. However, these methods are expensive and radioactive.

6 Jan 2014

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

14 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

ImmunoGen decides to stop IMGN901 Phase II SCLC study

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee.

6 Nov 2013

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.

23 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Antibody Drug Conjugate News and Research

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Collaboration classification useful for Japanese lung cancer patients

Apparent diffusion coefficient does not reflect cytotoxicedema on uninjured side after TBI

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

Alligator Bioscience acquires rights to drug development candidate ADC-1013

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Omnicell’s Pandora business analytics solutions now available in the Middle East markets

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ADC values and diffusion weighted imaging can be used to detect early cerebral infarction

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen decides to stop IMGN901 Phase II SCLC study

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

Pancreatic cancer patients may benefit from antibody-drug conjugates

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News